HLS Therapeutics
Provides access to treatments critical to patients and their caregivers with the brand names they trust.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
* | CAD107m | Post IPO Debt | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 7 % | 2 % | 3 % | (10 %) | 1 % | 10 % | 1 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 40 % | 34 % | 35 % | 33 % | 33 % | 35 % | 37 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (22 %) | (38 %) | (44 %) | (35 %) | (17 %) | (8 %) | (6 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
HLS Therapeutics Inc. is a pharmaceutical company dedicated to maintaining the heritage of life science products by introducing novel therapies and keeping trusted branded drugs on the market. The company primarily focuses on Central Nervous System (CNS) products and has successfully executed over 8 billion CAD in transactions within the pharmaceutical space. HLS serves healthcare providers, patients, and caregivers by providing access to high-quality medications that are critical to their needs. The company operates in the North American market, with a significant presence in both the United States and Canada. HLS Therapeutics generates revenue through the acquisition, development, and commercialization of pharmaceutical products, leveraging a rich portfolio of promoted and legacy therapies. The business model is centered around creating shareholder value through strategic acquisitions and growth initiatives.
Keywords: CNS products, pharmaceutical transactions, novel therapies, branded drugs, healthcare providers, North America, shareholder value, acquisition, commercialization, legacy therapies.